Kezar Life Sciences FY2025 operating loss narrows 34.8% to $(59) million; net loss narrows 33.1% to $(56) million

Reuters03-28

Kezar Life Sciences FY2025 operating loss narrows 34.8% to $(59) million; net loss narrows 33.1% to $(56) million

Kezar published its annual report on Form 10-K, reporting a net loss of USD 56 million.
Research and development expense fell 48.55% to USD 33.8 million, primarily due to lower clinical expenses after terminating the PALIZADE trial and completing the PORTOLA trial.
General and administrative expense declined 20.94% to USD 18.5 million, driven mainly by lower stock-based compensation and personnel costs following restructuring.
Restructuring and impairment charges rose more than tripled to USD 6.8 million, reflecting one-time severance costs and higher impairment on equipment no longer used after restructuring.
Cash and cash equivalents were USD 71.9 million, and management said this is expected to fund projected operating requirements for at least the next 12 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kezar Life Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-021737), on March 27, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622083438?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-28 04:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622083438","market":"us","top_or_hot":-1,"title":"Kezar Life Sciences FY2025 operating loss narrows 34.8% to $(59) million; net loss narrows 33.1% to $(56) million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kezar Life Sciences FY2025 operating loss narrows 34.8% to $(59) million; net loss narrows 33.1% to $(56) million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Kezar published its annual report on Form 10-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>, reporting a net loss of USD 56 million.\n        </li>\n<li>\n          Research and development expense fell 48.55% to USD 33.8 million, primarily due to lower clinical expenses after terminating the PALIZADE trial and completing the PORTOLA trial.\n        </li>\n<li>\n          General and administrative expense declined 20.94% to USD 18.5 million, driven mainly by lower stock-based compensation and personnel costs following restructuring.\n        </li>\n<li>\n          Restructuring and impairment charges rose more than tripled to USD 6.8 million, reflecting one-time severance costs and higher impairment on equipment no longer used after restructuring.\n        </li>\n<li>\n          Cash and cash equivalents were USD 71.9 million, and management said this is expected to fund projected operating requirements for at least the next 12 months.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/KZR\">Kezar Life Sciences Inc.</a> published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-021737), on March 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kezar Life Sciences FY2025 operating loss narrows 34.8% to $(59) million; net loss narrows 33.1% to $(56) million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKezar Life Sciences FY2025 operating loss narrows 34.8% to $(59) million; net loss narrows 33.1% to $(56) million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-28 04:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kezar Life Sciences FY2025 operating loss narrows 34.8% to $(59) million; net loss narrows 33.1% to $(56) million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Kezar published its annual report on Form 10-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>, reporting a net loss of USD 56 million.\n        </li>\n<li>\n          Research and development expense fell 48.55% to USD 33.8 million, primarily due to lower clinical expenses after terminating the PALIZADE trial and completing the PORTOLA trial.\n        </li>\n<li>\n          General and administrative expense declined 20.94% to USD 18.5 million, driven mainly by lower stock-based compensation and personnel costs following restructuring.\n        </li>\n<li>\n          Restructuring and impairment charges rose more than tripled to USD 6.8 million, reflecting one-time severance costs and higher impairment on equipment no longer used after restructuring.\n        </li>\n<li>\n          Cash and cash equivalents were USD 71.9 million, and management said this is expected to fund projected operating requirements for at least the next 12 months.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/KZR\">Kezar Life Sciences Inc.</a> published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-021737), on March 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KZR","symbol_name":"Kezar Life Sciences Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL8DXwND:1","article_id":"2622083438","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622083438","pubTimestamp":1774642604,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Kezar published its annual report on Form 10-K, reporting a net loss of USD 56 million.Research and development expense fell 48.55% to USD 33.8 million, primarily due to lower clinical expenses after terminating the PALIZADE trial and completing the PORTOLA trial.General and administrative expense declined 20.94% to USD 18.5 million, driven mainly by lower stock-based compensation and personnel costs following restructuring.Restructuring and impairment charges rose more than tripled to USD 6.8 million, reflecting one-time severance costs and higher impairment on equipment no longer used after restructuring.Cash and cash equivalents were USD 71.9 million, and management said this is expected to fund projected operating requirements for at least the next 12 months.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KZR":"Kezar Life Sciences Inc.","BK4139":"生物科技"},"translate_title":"Kezar Life Sciences 2025财年运营亏损收窄34.8%至(59)百万美元；净亏损收窄33.1%至(56)百万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KZR":0.9},"content_text":"Kezar Life Sciences FY2025 operating loss narrows 34.8% to $(59) million; net loss narrows 33.1% to $(56) million\n    \n\n\n          Kezar published its annual report on Form 10-K, reporting a net loss of USD 56 million.\n        \n\n          Research and development expense fell 48.55% to USD 33.8 million, primarily due to lower clinical expenses after terminating the PALIZADE trial and completing the PORTOLA trial.\n        \n\n          General and administrative expense declined 20.94% to USD 18.5 million, driven mainly by lower stock-based compensation and personnel costs following restructuring.\n        \n\n          Restructuring and impairment charges rose more than tripled to USD 6.8 million, reflecting one-time severance costs and higher impairment on equipment no longer used after restructuring.\n        \n\n          Cash and cash equivalents were USD 71.9 million, and management said this is expected to fund projected operating requirements for at least the next 12 months.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kezar Life Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-021737), on March 27, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622083438","isCrawlerRequest":true}